Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

APVOBullishCorporate Developmentsnews

High materiality8/10

Aptevo Advances AML Mipletamig, Adds CSO, and Expands into Radiopharma with Niowave

Aug 14, 2026, 8:07 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive data (87%/81%), Phase 2 readout potential, non-dilutive funding, and radiopharma collaboration collectively expand value drivers; cash runway modest but improving; multiple near-term catalysts support upside til 1Q27.

AI summary

What happened, with direct paths to the underlying reporting

Aptevo reported Q2 2026 results with mipletamig showing strong frontline AML activity and a path to Phase 2 in 1Q27. The company added a CSO, secured a $1.5 million CARE grant for APVO451, and launched a 50/50 radiopharmaceutical collaboration with Niowave, backed by a Niowave equity stake, while holding $9.8 million in cash. These moves broaden the pipeline and optionality.

Mipletamig shows strong frontline AML data; Phase 2 path targeted for 1Q27.
CSO appointment strengthens execution across expanding oncology pipeline.
Non-dilutive CARE grant advances APVO451 IND-enabling work.
Niowave 50/50 collaboration creates radiopharmaceutical development pathway.
Q2 2026 cash $9.8M; SEPAs raised $0.6M.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Aptevo Advances AML Mipletamig, Adds CSO, and Expands into Radiopharma with Niowave

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer